linjc16/ctgov huggingface dataset:
Petro-trigeminal Line and Petrous Apex Cephaloceles

Study Overview
=================
Brief Summary
-----------------
cephaloceles are rare lesions of the petrous apex, inconsistently listed as meningoceles or arachnoid cysts. They're consistent with a herniation posterolateral of the Meckel cavum within the petrous apex. These lesions may be the cause of a symptomatology varied, or be discovered by chance in subjects who have not been asymptomatic. Currently, there is no evidence in the literature a simple, fast and reproducible radiological marker that allows for the diagnosis of cephaloceles of the petrous apex, in particular the small ones. The purpose of this study is to validate a radiological benchmark simple and reproducible, the trigeminal petrol line, in order to improve the diagnosis of petrous apex cephaloceles

Official Title
-----------------
The Petro-trigeminal Line: a Simple Radiological Marker for the Diagnosis of Cephaloceles of the Petrous Apex on MRI

Conditions
-----------------
Petrous Apex Meningioma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Major subjects (≥18 years old) patients who underwent an MRI with high resolution 3D T2 sequence between 01/01/2003 and 09/31/2020: 200 patients consulting for ENT pathology such as vertigo 9 patients presenting the radiological criteria in MRI of a cephalocele of the petrous apex according to the current data of the literature on a T2 3D HR sequence - Subject who has not expressed his opposition, after being informed, to the reuse of his data for the purposes of this research. Exclusion criteria: Subject who expressed their opposition to participating in the study Kinetic Artifacts Subject under guardianship or curatorship Subject under safeguard of justice

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Validate a radiological landmark allowing MRI diagnosis cephaloceles of the petrous apex | This mark corresponds to the projection of a line drawn on an axial section, in the plane of the posterior roots of the trigeminal nerves, between the anterior and external edges of the petrous apex along the petro-trigeminal angle on each side. | Files analysed retrospectively from from January 01, 2003 to September 31, 2020 will be examined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Petrous apex cephaloceles, Petrous apex, meckel's cave, cavum-trigeminale-cephaloceles, arachnoïd kyst, meningoceles, trigeminal nerves
A Trial on Conservative Treatment for Infants' Hirschsprung Disease

Study Overview
=================
Brief Summary
-----------------
The present study was designed to compare the efficacy of conservative treatment to operative treatment for improvement of constipation symptoms in infants with short or normal-segment Hirschsprung disease.

Official Title
-----------------
A Prospective, Randomized Controlled Trial of Conservative Versus Surgery Treatment of Normal and Short-segment Hirschsprung Disease for Infants

Conditions
-----------------
Hirschsprung Disease

Intervention / Treatment
-----------------
* Procedure: surgery treatment
* Behavioral: anal dilation
* Behavioral: colonic lavage
* Drug: oral probiotic


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hard or firm stools for twice or less per week Age were from newborn to 3 months Histochemical acetylcholinesterase reaction (AChE) in rectal mucosa was positive The narrowed distal bowel on barium enema was characterized as normal or short-segment Hirschsprung disease with a 24h barium retention Exclusion Criteria: Children >3months of age Patients presented severe inflammation or malnutrition, unconsciousness, and symptoms of a ruptured hollow viscus Barium enema showed long-segment or total colonic aganglionic bowel

Ages Eligible for Study
-----------------
Maximum Age: 3 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: surgery treatment<br>one stage pull through left-colectomy | Procedure: surgery treatment<br>* one staged pull-through left-colectomy<br>|
| Experimental: conservative treatment<br>anal dilation, colonic lavage, oral probiotic | Behavioral: anal dilation<br>* anal dilation<br>Behavioral: colonic lavage<br>* colonic lavage<br>Drug: oral probiotic<br>* oral probiotic<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the change of defecation frequence | the changes of defecation frequence at 6 12 months after treatment | 6 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| stool pattern | stool pattern as Forming soft stool or Loose stool | 6 12 months | 
| controlling defecation ability | whether patients' controlling of defecation be better or not after treatment | 6 12 months | 
| complications | complications were suffered by patients or not, such as enterolitis, anastomotic stenosis etc. | 6 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hirschsprung disease, conservative treatment, surgery treatment, infants
The Effects of Overfeeding on Obesity-Prone (OP) and Obesity-Resistant (OR) Women

Study Overview
=================
Brief Summary
-----------------
This is a longitudinal cohort study of how the responses to a 3 day period of controlled overfeeding relate to subsequent weight gain. We hypothesize that thin individuals are resistant to weight gain because they respond to periods of overfeeding by increasing fat oxidation, reducing food intake, and increasing physical activity relative to those who gain weight over time.

Official Title
-----------------
The Effects of Overfeeding on Obesity-Prone (OP) and Obesity-Resistant (OR) Women

Conditions
-----------------
Obesity, Thinness, Weight Gain

Participation Criteria
=================
Eligibility Criteria
-----------------
Half of the subjects will be women, half will be men, age 25-35, a range of BMI's from 19-27, for the 'thin subjects' there should be no 1st degree relatives with a BMI>30. Subjects should not engage in planned physical activity more than 3 hrs per week. For the obesity prone group there should be at least 1 1st degree relative with a BMI>30.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
obesity, thinness, weight gain, physical activity, diet, fat oxidation, hunger, feeding behavior, overfeeding
A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
The purpose of this clinical research study is to support earlier observations that Glucovance controls glucose levels after a mean, and improves overall glucose control better than metformin or glyburide therapy alone in adults with type 2 diabetes.

Conditions
-----------------
Diabetes Mellitus, Non-Insulin-Dependent

Intervention / Treatment
-----------------
* Drug: Glucovance (metformin HCl/glyburide)
* Drug: or Metformin HCl alone
* Drug: or Glyburide alone.


Participation Criteria
=================
Eligibility Criteria
-----------------
Adults 20-75 with a diagnosis of type 2 diabetes mellitus who are not adequately controlled with diet and exercise, and have an HbA1c greater than 6.7%

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Glucovance (metformin HCl/glyburide)|nan|
|Drug: or Metformin HCl alone|nan|
|Drug: or Glyburide alone.|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Type 2 Diabetes Mellitus
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
This is a double-blind, randomized, placebo-controlled, single ascending dose study to assess the safety, tolerability, and PK of ACHN-975 in normal healthy volunteers. This study will take place in the US at one clinical site.

Official Title
-----------------
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) ACHN-975 in Normal Healthy Volunteers

Conditions
-----------------
Healthy Volunteer

Intervention / Treatment
-----------------
* Drug: ACHN-975
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Body weight between 40 and 100 kilograms (between  88 pounds and  220 pounds) Use of contraception Stable health Negative tests for alcohol, tobacco, and drugs of abuse Key Exclusion Criteria: History of clinically significant disease Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm A<br> | Drug: ACHN-975<br>* Intravenous single dose<br>|
| Placebo Comparator: Arm B<br> | Drug: placebo<br>* Intravenous single dose<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of AEs |  | 7 days | 
| Severity of AEs |  | 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma concentrations of ACHN-975 |  | 2 days | 
| Urine concentrations of ACHN-975 |  | 2 days |
Effects of Milk Derived From Mountain-pasture Grazing Cows on Risk Markers of the Metabolic Syndrome Compared to Conventional Danish Milk

Study Overview
=================
Brief Summary
-----------------
To investigate the effect of milk delivered from mountain-pasture grazing cows on risk markers of the metabolic syndrome and type-2 diabetes with the effect of conventional Danish milk. The study should reveal the importance of phytanic acid content for these effects.

Official Title
-----------------
Effects of Milk Derived From Mountain-pasture Grazing Cows on Risk Markers of the Metabolic Syndrome Compared to Conventional Danish Milk

Conditions
-----------------
Coronary Heart Disease, Type-2 Diabetes

Intervention / Treatment
-----------------
* Dietary Supplement: milk fat


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: sign written consent Age: 50-70 BMI: 20-30 increased risk of developing MS refrain from dietary supplements and blood donations prior to, and during the study Exclusion Criteria: poor compliance if they suffering from any chronic or long lasting illness abuse of alcohol or medicine

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Dietary Supplement: milk fat|39 g milk fat per day in 12 weeks|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oral glucose tolerance test |  | before and after the intervention (12 weeks) | 
| LDL cholesterol |  | before and after the intervention (12 weeks) | 
| HDL cholesterol |  | before and after the intervention (12 weeks) | 
| Total cholesterol |  | before and after the intervention (12 weeks) | 
| Triacylglycerol |  | before and after the intervention (12 weeks) | 
| C-reactive protein |  | before and after the intervention (12 weeks) | 
| fatty acid composition in plasma |  | before and after the intervention (12 weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| phytanic acid |  | before and after the intervention (12 weeks) |
Treatment Modification to Reduce Symptom Burden in Hemodialysis

Study Overview
=================
Brief Summary
-----------------
Many patients on hemodialysis experience high rates of symptom burden, such as pain, depression, anxiety and difficulty breathing. This study seeks to reduce these symptoms by modifying the usual guidelines used to manage patients on hemodialysis. For example, rather than trying to keep serum phosphorus below 5.5, patients enrolled in this study may have treatment goals of less than 6.5, in order to reduce the number of pills they need to take and potentially reduce harmful side effects. Blood pressure and serum parathyroid hormone goals will also be modified, to see if these modifications help hemodialysis patients feel better.

Official Title
-----------------
Treatment Modification and Symptom Burden in High-Risk Dialysis Patients

Conditions
-----------------
End Stage Renal Disease

Intervention / Treatment
-----------------
* Other: Treatment modification


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hemodialysis patient transplant ineligible Exclusion Criteria: dementia unable to answer questionnaires for any reason
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment modification<br>Patients in this arm will be treated to different targets of blood pressure, parathyroid hormone and serum phosphorus. | Other: Treatment modification<br> <br> |
| No Intervention: Usual care<br>Patients will receive the usual hemodialysis care with no modifications | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants Recruited, Consented, Randomized and Completed |  | Each participant was assessed for 6 weeks; total recruitment period was 15 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptom Burden | Number of symptoms in past week as measured by the Dialysis Symptom Index | Baseline and 6 weeks |
Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether patients with asthma are better able to manage and control their symptoms by using one inhaler daily that both prevents as well as treats the symptoms of an asthma exacerbation.

Official Title
-----------------
Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: Budesonide/formoterol
* Device: Symbicort® Turbohaler®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged over 18 Confirmed diagnosis of mild to moderate asthma by doctor Currently receiving inhaled corticoid-steroid medicine for treatment of asthma and requiring a review of current asthma treatment Exclusion Criteria: Women who are pregnant, breast-feeding, or planning pregnancy Patients with a history of chronic obstructive pulmonary disease Patients using any beta blocker therapy Patients receiving steroid tablets or steroid injections

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Budesonide/formoterol|nan|
|Device: Symbicort® Turbohaler®|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In a real life setting, to compare Symbicort® Single Inhaler Therapy with a patient's previous therapy (including low dose ICS), by assessment of the changes in the Asthma Control Questionnaire score in uncontrolled asthmatic patients. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in forced expiratory volume in one second (FEV1) |  |  | 
| Change in peak expiratory flow (PEF) |  |  | 
| Patient Reported Outcomes: AQLQ(S), SATQ, RCP-3 scores |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Respiratory Tract Diseases, Bronchial Diseases, Anti-asthmatic agents, Anti-asthmatic drugs, Bronchodilators
Mechanistic Studies on Video-guided Acupuncture Imagery Treatment of Knee Pain

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to investigate brain response and connectivity changes evoked by video-guided acupuncture imagery treatment (VGAIT) and verum and sham acupuncture in knee osteoarthritis patients to elucidate the underlying brain mechanisms of mind-body interaction, imagery, and acupuncture.

Official Title
-----------------
Mechanistic Studies on Video-guided Acupuncture Imagery Treatment of Knee Pain

Conditions
-----------------
Osteoarthritis, Knee

Intervention / Treatment
-----------------
* Device: Acupuncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Right-handed Knee osteoarthritis patients Ages 40 to 70 years old Exclusion Criteria: Any contraindications to MRI scanning (claustrophobia, metal implants) Current or past history of major medical, neurological, or psychiatric illness other than knee osteoarthritis (including high blood pressure, heart disorders, impaired elimination, stomach problems, major kidney or liver problems, bleeding problems, severe dehydration, history of diabetes, history of asthma or other respiratory condition) Pregnancy Non fluent English speaker

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: VGAIT<br> | Device: Acupuncture<br>* Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.<br>* Other names: Video of Acupuncture;|
| Sham Comparator: VGAIT Control<br> | Device: Acupuncture<br>* Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.<br>* Other names: Video of Acupuncture;|
| Active Comparator: Real Acupuncture<br> | Device: Acupuncture<br>* Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.<br>* Other names: Video of Acupuncture;|
| Placebo Comparator: Sham Acupuncture<br> | Device: Acupuncture<br>* Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.<br>* Other names: Video of Acupuncture;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fMRI signal increases |  | 4 days; Sessions 2-5 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fMRI, acupuncture, osteoarthritis